METHOD DEVELOPMENT AND VALIDATION OF A REVERSED-PHASE LIQUID CHROMATOGRAPHIC METHOD FOR THE SIMULTANEOUS ESTIMATION OF SELECTED ANTIDIABETIC DRUGS IN THE PRESENCE OF THEIR DEGRADATION PRODUCTS
DOI:
https://doi.org/10.22159/ajpcr.2018.v11i10.27083Keywords:
Metformin, Sitagliptin, Pioglitazone, Glimepiride, stress testing, degradation products, stability-indicating method, HPLCAbstract
 Â
 Objective: This study was designed to conduct forced degradation and validation studies for the simultaneous estimation of metformin, sitagliptin, pioglitazone, and glimepiride.
Methods: Analytes were separated on an Agilent XDB-C18, 150 × 4.6 mm, 5 μm column using an isocratic elution mode having mobile phase composition of 20 mM potassium dihydrogen phosphate buffer (pH 4.0):acetonitrile (65:35% v/v). Analytes were detected at a wavelength of 225 nm. The optimized method was validated as per the ICH Q2 guidelines.
Results: The retention times of metformin, sitagliptin, pioglitazone, and glimepiride were 3.47, 4.83, 5.83, and 9.44 min, respectively. The linearity was 25–100 μg/ml for metformin, 2.5–10 μg/ml for sitagliptin, 1–4 μg/ml for pioglitazone, and 0.75–3 μg/ml for glimepiride. The correlation coefficient for calibration curves was >0.99, and accuracy was between 98 and 102% for each analyte. Inter- and intra-day precisions were calculated <2% relative standard deviation for each analyte.
Conclusion: A significant degradation was observed in the presence of acidic, basic, neutral, oxidative, and photolytic stress conditions. The method is simple, precise, accurate, robust, and reproducible and was able to successfully separate and quantify metformin, sitagliptin, pioglitazone, and glimepiride in the presence of their degradation products.
Downloads
References
Steinberg H, Anderson MS, Musliner T, Hanson ME, Engel SS. Management of dyslipidemia and hyperglycemia with a fixed-dose combination of sitagliptin and simvastatin. Vasc Health Risk Manag 2013;9:273-82.
Brunzell JD, Davidson M, Furberg CD, Goldberg RB, Howard BV, Stein JH, et al. Lipoprotein management in patients with cardiometabolic risk: Consensus conference report from the American diabetes association and the American college of cardiology foundation. J Am Coll Cardiol 2008;51:1512-24.
National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third report of the national cholesterol education program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult treatment panel III) final report. Circulation 2002;106:3143-421.
Genest J, McPherson R, Frohlich J, Anderson T, Campbell N, Carpentier A, et al 2009 Canadian cardiovascular society/Canadian guidelines for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease in the adult - 2009 recommendations. Can J Cardiol 2009;25:567-79.
Pedersen TR, Kjekshus J, Berg K, Haghfelt T, Faergeman O, Faergeman G, et al. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian simvastatin survival study (4S). 1994. Atheroscler Suppl 2004;5:81-7.
Cannon CP, Braunwald E, McCabe CH, Rader DJ, Rouleau JL, Belder R, et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 2004;350:1495-504.
LaRosa JC, Grundy SM, Waters DD, Shear C, Barter P, Fruchart JC, et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 2005;352:1425-35.
Cheong C, Barner JC, Lawson KA, Johnsrud MT. Patient adherence and reimbursement amount for antidiabetic fixed-dose combination products compared with dual therapy among texas medicaid recipients. Clin Ther 2008;30:1893-907.
Pan F, Chernew ME, Fendrick AM. Impact of fixed-dose combination drugs on adherence to prescription medications. J Gen Intern Med 2008;23:611-4.
Thayer S, Arondekar B, Harley C, Darkow TE. Adherence to a fixed-dose combination of rosiglitazone/glimepiride in subjects switching from monotherapy or dual therapy with a thiazolidinedione and/or a sulfonylurea. Ann Pharmacother 2010;44:791-9.
Drucker DJ, Nauck MA. The incretin system: Glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet 2006;368:1696-705.
Herman GA, Stein PP, Thornberry NA, Wagner JA. Dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes: Focus on sitagliptin. Clin Pharmacol Ther 2007;81:761-7.
drugs/DB00222. 17. Drug profile for Pioglitazone. Available From: https://www.drugbank.
Available from: https://www.clinicaltrials.gov/ct2/show/NCT01678820.
Drug Profile for Sitagliptin. Available from: http://www.drugbank.ca/ drugs/DB01261.
Drug Profile for Metformin. Available from: http://www.drugbank.ca/ drugs/DB00331.
Drug Profile for Glimepiride. Available from: http://www.drugbank.ca/ drugs/DB00222.
ca/drugs/DB01132.
Drug profile for Pioglitazone. Available From: https://www.drugbank.
ICH and Q2B, Harmonized Tripartite Guideline, Validation of
Analytical Procedure: Methodology, IFPMA, in Proceedings of the International Conference on Harmonization; 1996.
Shyamala M, Mohideen S, Satyanarayana T, Sures P. Validated RP-HPLC For simultaneous estimation of sitagliptin phosphate and metformin hydrochloride in tablet dosage form. Am J Pharma Res 2011;1:93-101.
Kashid AM, Dhange AA, Gavande VT, Miniyar PB. RP-HPLC method development and validation for sitagliptin in human plasma. Am J Pharma Res 2012;2:805-11.
Loni AB, Ghante MR, Sawant SD. Simultaneous UV spectrophotometric method for estimation of sitagliptin phosphate and metformin hydrochloride in bulk and tablet dosage form. Der Pharma Chemica 2012;4:854-9.
Jeyabalan G, Nyola N. Simultaneous estimation of sitagliptin phosphate monohydrate and metformin hydrochloride in bulk and pharmaceutical formulation by RP-HPLC. J Pharm Educ Res 2012;3:24-8.
Phaneemdra D, Venktesh V, Ramarao N. simultaneous estimation of simvastatin and sitagliptin by using different analytical methods. Int J In Adv In Pharma Anal 2012;2:19-23.
Lavanya R, Yunoos MD. Development and validation of RP-HPLC method for the estimation of sitagliptin phosphate in bulk and its tablet dosage form. J Adv Pharm Edu Res 2013;3:475-9.
Salim M, El-Enany N, Belal F, Walash M, Patonay G. Simultaneous determination of Sitagliptin and metformin in pharmaceutical preparations by capillary zone electrophoresis and its application to human plasma analysis. Anal Chem Insights 2012;7:31-46.
Warghade SV, Devlekar ND, Patil RY, Barge VU. Validated HPTLC method for simultaneous estimation of metformin hydrochloride and sitagliptin phosphate in bulk drug and pharmaceutical formulation. J Pharm Anal 2014;5:2340-7.
Kumar SA, Debnath M, Rao LN. Development of stability indicating RP- HPLC method for simultaneous estimation of metformin hydrochloride and sitagliptin phosphate monohydrate in bulk as well as in pharmaceutical formulation. Der Pharmacia Sinica 2013;4:47-61.
Malleswararao CS, Suryanarayana MV, Mukkanti K. Simultaneous determination of sitagliptin phosphate monohydrate and metformin hydrochloride in tablets by a validated UPLC method. Sci Pharm 2012;80:139-52.
Ramalingam P, Bhaskar VU, Reddy YP, Kumar KV. Stability-indicating RP-HPLC method for the simultaneous determination of sitagliptin and simvastatin in tablets. Indian J Pharm Sci 2014;76:407-14.
Sharma S, Manocha N. estimation of sitagliptin phosphate and simvastatin and validation of the proposed method in a combined marketed tablet dosage form by simultaneous equation method. Int J of Current Pharma Res 2012;4:144-7.
Kar M, Choudhury PK. HPLC method for estimation of metformin hydrochloride in formulated microspheres and tablet dosage form. Indian J Pharm Sci 2009;71:318-20.
Vasudevan M, Ravi J, Ravisankar S, Suresh B. Ion-pair liquid chromatography technique for the estimation of metformin in its multicomponent dosage forms. J Pharmaceut Biomed 2001;25:77-84.
Gandhimathi M, Anandakumar K, Cheriyan A, Ravi T. Simultaneous estimation of metformin and gliclazide in tablets using reverse phase high performance liquid chromatography. Indian J Pharm Sci 2003;65:530-1.
Lad NR, Bhoir SI, BhoirI C, Sundaresan M. Concurrent assay of metformin and glimepiride in tablets using RP-HPLC with wavelength programming. Indian J Pharm Sci 2003;65:650-3.
Sahoo PK, Sharma R, Chaturvedi SC. Simultaneous estimation of metformin hydrochloride and pioglitazone hydrochloride by RP-HPLC method from combined tablet dosage form. Indian J Pharm Sci 2008;70:383-6.
Swetha A, Kuber BR. A novel stability-indicating reverse phase liquid chromatographic method for the simultaneous estimation of metformin and teneligliptin in pure and pharmaceutical formulations. Int J Pharm Pharm Sci 2017;9:163-9.
Jayaprakash R, Natesan SK. Stability indicating RP-HPLC method development and validation for the simultaneous determination of vildagliptin and metformin in pharmaceutical dosage form. Int J Pharm Pharm Sci 2017;9:150-7.
Published
How to Cite
Issue
Section
The publication is licensed under CC By and is open access. Copyright is with author and allowed to retain publishing rights without restrictions.
